TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014. QVAR- is an inhaled corticosteroid (ICS) indicated in the maintenance treatment of asthma as a prophylactic therapy in patients 5 years of age and older.

Data to be presented at the meeting evaluated the benefit of treating asthma with small particle treatments, like QVAR-, in comparison to a larger particle treatment. The data from the study was gathered over one year from the UK Optimum Patient Care Database and Clinical Practice Research Datalink.

"The findings of the study revealed interesting differences in asthma exacerbation outcome rates based on the level of initiation dosing with small versus large particle ICS treatments," said Dr. David Price, Professor of Primary Care Respiratory Medicine, University of Aberdeen Center of Academic Care and lead investigator of the study.

The below QVAR- data will be presented during a thematic poster session on May 18 from 8:15 a.m. to 4:30 p.m. PDT in the exhibit hall at the ATS Annual International Conference:

ID 52087 Impact Of Inhaled Corticosteroid (ICS) Particle Size on Dose-Response Curves (A37 - Cost, Technology, and Comparative Effectiveness)

"Retrospective studies that use real-word databases, like this one, help provide a clearer picture of effectiveness of treatments in actual practice among a broad patient population. The data to be presented at ATS further validates the use of small particle ICS therapy in achieving overall asthma control," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "Teva remains committed to providing safe, effective and affordable options, like QVAR-, for the more than 300 million patients in the world with asthma."